2 citations
,
January 2023 in “Frontiers in Oncology” Mild oxidative stress can prevent hair loss from chemotherapy.
4 citations
,
May 2023 in “Research Square (Research Square)” Cepharanthine can potentially treat gastric cancer by stopping tumor growth.
28 citations
,
December 2001 in “European Journal of Pharmacology” M50054 may help treat hepatitis and hair loss from chemotherapy.
Green tea compound EGCG could potentially treat colorectal cancer by removing iron and causing stress in cancer cells leading to their death.
6 citations
,
September 2022 in “Frontiers in pharmacology” Epimedium extract helps increase skin pigmentation and could be a new treatment for conditions with reduced pigmentation.
1 citations
,
January 2009 in “Actas Dermo-Sifiliográficas” Docetaxel, a chemotherapy drug, was reported to cause psoriasis in a patient for the first time.
June 2025 in “British Journal of Dermatology” Ritlecitinib may cause serious side effects like blood clots in alopecia areata patients.
May 2025 in “Dermatology Online Journal” Erlotinib can cause excessive eyelash growth.
1 citations
,
February 2020 in “The Journal of clinical investigation/The journal of clinical investigation” Certain cancer drugs interact with skin bacteria to cause acne-like rashes.
March 2012 in “Reactions Weekly” A man had a rare skin reaction from a hair loss medication, which improved after stopping the drug.
23 citations
,
November 2015 in “Phytotherapy Research” Certain herbal compounds, especially from bitter melon, can inhibit cancer growth and promote hair growth by blocking PAK1.
January 2022 in “Dermatology Review” EGFR inhibitors can cause unusual localized hair growth.
59 citations
,
March 2003 in “The Lancet” Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.
MVP treatment is effective and safe for recurrent breast cancer.
43 citations
,
March 2017 in “Drug Design Development and Therapy” The new nanoparticles could improve melanoma treatment by working better than current options.
August 2018 in “Dermatologic Surgery”
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
3 citations
,
April 1977 in “PubMed” The treatment improved acne, seborrhoea, and hirsutism, with some side effects like spotting and nervousness.
December 2023 in “Frontiers in oncology” Older ovarian cancer patients live longer and tolerate weekly chemotherapy better than three-weekly treatments.
2 citations
,
February 2025 in “Journal of the American Pharmacists Association”
5 citations
,
January 2018 in “Skin Pharmacology and Physiology” Curcuma aeruginosa extract lotion significantly reduces underarm hair growth.
April 2025 in “Journal of Pharma Insights and Research.” Females had more chemotherapy side effects than males, with many being preventable.
43 citations
,
January 2014 in “Indian Journal of Dermatology” EGFR inhibitors can cause skin issues like acne and dryness, but these can be managed without stopping treatment.
22 citations
,
November 2002 in “Clinical journal of oncology nursing” Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.
7 citations
,
January 2009 in “BMJ Case Reports” Gefitinib can cause slower, finer, brittle, and curly scalp hair.
17 citations
,
May 2019 in “Journal of International Medical Research” Xiaoaiping reduces chemotherapy side effects and improves quality of life for breast cancer patients.
2 citations
,
February 2020 in “Annual Research & Review in Biology” Eruca sativa oil, Aloe vera oil, and sodium carbonate may help improve cholesterol and tumor markers in breast cancer treatment.
January 2025 in “Regenerative Biomaterials” The cerium-polypeptide hydrogel effectively heals drug-resistant bacterial wounds by fighting bacteria, reducing inflammation, and promoting tissue repair.
June 2023 in “Journal of Clinical Oncology” CDK4/6 inhibitors may cause hair loss in breast cancer patients.
1 citations
,
May 2022 in “The FASEB journal” The document concludes that biotin, folate, and RGD peptides are promising for targeting cancer cells with prodrugs, but the conjugates are not yet tested for use.